Daratumumab is safe and induces a rapid hematological response in light-chain amyloidosis with severe cardiac impairment
暂无分享,去创建一个
F. Lemonnier | C. Haioun | A. Maarek | T. Damy | J. Dupuis | L. Roulin | K. Belhadj | A. Beldi-Ferchiou | F. Le Bras | V. Molinier-Frenkel | D. Bodez | E. Poullot | S. Oghina | R. Gounot | A. Ladaique
[1] M. Maurer,et al. Daratumumab Plus CyBorD for Patients With Newly Diagnosed AL Amyloidosis: Safety Run-in Results of ANDROMEDA. , 2020, Blood.
[2] D. Hose,et al. Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic range albuminuria. , 2020, Blood.
[3] S. Sarosiek,et al. Safety, Tolerability, and Response Rates of Daratumumab in Relapsed AL Amyloidosis: Results of a Phase II Study. , 2020, Blood.
[4] P. Hawkins,et al. A prospective observational study of 915 patients with systemic AL amyloidosis treated with upfront bortezomib. , 2019, Blood.
[5] D. Dingli,et al. Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis , 2018, Leukemia.
[6] J. Zonder,et al. Daratumumab proves safe and highly effective in AL amyloidosis , 2018, British journal of haematology.
[7] P. Morel,et al. A Prospective Phase II of Daratumumab in Previously-Treated Systemic Light-Chain (AL) Amyloidosis , 2017 .
[8] S. Schrier,et al. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. , 2017, Blood.
[9] A. Foli,et al. A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis. , 2017, Blood.
[10] P. Hawkins,et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens , 2014, British journal of haematology.
[11] P. Hari,et al. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III) , 2014, Haematologica.
[12] M. Dimopoulos,et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. , 2013, Blood.
[13] M. Dimopoulos,et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Falk,et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis , 2005, American journal of hematology.
[15] T. Therneau,et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.